High-yield points
- Effect lasts about 12 weeks .
- Systemic events (incontinence about 1%, respiratory admissions 1.3%) rise with GMFCS level and dose .
- Common targets: calf (equinus), hamstrings, adductors, tibialis posterior; biceps, pronator teres, wrist and finger flexors, thumb (see caveats).
- Phenol obturator blocks for adductor tone .
Indications
- Focal or segmental spasticity interfering with function, care, positioning or orthotic wear (see spasticity surgery).
- Effect: a modest, time-limited tone reduction (about 12 weeks) .
- Often combined with casting, orthoses and physical therapy (see caveats).
Basic procedural flow
- Technique (see caveats):
- ultrasound, EMG or electrical stimulation guidance to localize the muscle;
- sedation or topical anesthesia;
- dose by body weight, spread among muscles, under a total-dose ceiling.
- Common lower-limb targets (see caveats):
- gastrocnemius and soleus for equinus (toe walking);
- hamstrings (medial) for crouch and knee flexion;
- hip adductors for scissoring and hip migration;
- iliopsoas for hip flexion;
- tibialis posterior for varus foot;
- rectus femoris for stiff-knee gait.
- Common upper-limb targets (see caveats):
- biceps and brachioradialis for elbow flexion;
- pronator teres for forearm pronation;
- flexor carpi ulnaris and radialis for wrist flexion;
- finger flexors;
- adductor pollicis and first dorsal interosseous for thumb-in-palm.
- Phenol blocks (for example of the obturator nerve for the adductors) gave tone reduction lasting more than 6 months , and can spare toxin dose (see caveats).
Risks
- Systemic adverse events : incontinence about 1% and respiratory admissions about 1.3%, linked to GMFCS level and dose.
- Other systemic risks (see caveats): generalized weakness and dysphagia with aspiration.
- Local risks (see caveats):
- pain and bruising;
- excessive weakness of the injected muscle;
- antibody formation with frequent dosing.
Postoperative management
- Therapy and casting in the weeks after injection, when tone is lowest (see caveats).
- Reinject no sooner than about every 3 months; reassess goals each cycle (see caveats).
- Warn families about swallowing or breathing problems, especially in GMFCS IV–V children (see caveats).
Related topics
- Surgical Management of Spasticity in Children (Botulinum Toxin, Phenol, Intrathecal Baclofen, Selective Dorsal Rhizotomy): where toxin fits.
- Spasticity vs. Dystonia: Mechanisms and Clinical Distinction: treating the right problem.
- Principles of Pediatric Neuro-Rehabilitation: therapy after injection.
- Intrathecal Baclofen Pump Implantation: for generalized spasticity.
- Selective Dorsal Rhizotomy: permanent tone reduction in spastic diplegia.
References
- Alghadier M, Alsuwayegh A. Efficacy of botulinum toxin type A for spasticity management and motor function in children with cerebral palsy: a systematic review and meta-analysis of randomized controlled trials. Front Neurol 2026;17:1751493. doi:10.3389/fneur.2026.1751493. PMID 41809197. verified
- Kwon JY, Kim JS. Selective blocking of the anterior branch of the obturator nerve in children with cerebral palsy. Am J Phys Med Rehabil 2009;88(1):7–13. doi:10.1097/PHM.0b013e31815b6381. PMID 17993980. verified
- Naidu K, Smith K, Sheedy M, et al. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy. Dev Med Child Neurol 2010;52(2):139–144. doi:10.1111/j.1469-8749.2009.03583.x. PMID 20412252. verified
Verification (2026-11-19):
- Each reference was checked on PubMed (authors, title, journal, year, volume, pages, DOI, PMID), and the statements attributed to it against its abstract. These references were verified for the spasticity surgery topic.
Caveats:
- The following are standard teaching, not drawn from the cited abstracts:
- combination with casting and therapy
- injection guidance, dosing principles and the muscle-by-muscle targets
- local risks, antibody formation, generalized weakness and dysphagia, and toxin-sparing with phenol
- post-injection therapy, reinjection interval and family warnings